EA200000656A1 - Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение - Google Patents

Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение

Info

Publication number
EA200000656A1
EA200000656A1 EA200000656A EA200000656A EA200000656A1 EA 200000656 A1 EA200000656 A1 EA 200000656A1 EA 200000656 A EA200000656 A EA 200000656A EA 200000656 A EA200000656 A EA 200000656A EA 200000656 A1 EA200000656 A1 EA 200000656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
tiazolidindion
derivative
substituted
obtaining
Prior art date
Application number
EA200000656A
Other languages
English (en)
Other versions
EA002833B1 (ru
Inventor
Ян Роберт Линч
Бернадетт Мари Чаудари
Майкл Джон Сэсс
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200000656A1 publication Critical patent/EA200000656A1/ru
Publication of EA002833B1 publication Critical patent/EA002833B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

(57) Гидрат соли малеиновой кислоты 5-[4-[2-(N-метил-N-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона, отличающийся тем, что он: (i) включает воду в интервале от 0,3 до 0,6 мольных эквивалентов; и (ii) имеет инфракрасный спектр, содержащий пики при 1757, 1331, 1290/ 1211 и 767 см; и/или (iii) имеет спектр Рамана, содержащий пики при 1758, 1610, 1394, 1316 и 1289 см; и/или (iv) в твердом состоянии имеет спектр ядерно-магнитного резонанса, содержащий в основном химические сдвиги, которые приведены здесь в таблице I; и/или (v) имеет картину дифракции рентгеновских лучей в порошке (РЛПД), в основном соответствующую приведенной здесь на фигуре IV; способ получения такого соединения, фармацевтическая композиция, содержащая такое соединение, и применение такого соединения или композиции в медицине.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000656A 1997-12-16 1998-12-14 Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение EA002833B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726563.1A GB9726563D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical
PCT/EP1998/008153 WO1999031093A1 (en) 1997-12-16 1998-12-14 Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use

Publications (2)

Publication Number Publication Date
EA200000656A1 true EA200000656A1 (ru) 2000-12-25
EA002833B1 EA002833B1 (ru) 2002-10-31

Family

ID=10823691

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000656A EA002833B1 (ru) 1997-12-16 1998-12-14 Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение

Country Status (37)

Country Link
US (4) US20020133016A1 (ru)
EP (1) EP1042321A1 (ru)
JP (1) JP2002508371A (ru)
KR (1) KR100549141B1 (ru)
CN (3) CN1285831A (ru)
AP (1) AP1363A (ru)
AR (2) AR016161A1 (ru)
AU (2) AU2272299A (ru)
BG (1) BG64850B1 (ru)
BR (1) BR9813598A (ru)
CA (1) CA2314967A1 (ru)
CO (1) CO4990943A1 (ru)
CZ (1) CZ300081B6 (ru)
DZ (1) DZ2679A1 (ru)
EA (1) EA002833B1 (ru)
EG (1) EG22250A (ru)
GB (1) GB9726563D0 (ru)
HR (1) HRP20000404A2 (ru)
HU (1) HUP0102292A3 (ru)
ID (1) ID24714A (ru)
IL (2) IL136425A (ru)
MA (1) MA26581A1 (ru)
MY (1) MY128573A (ru)
NO (1) NO317255B1 (ru)
NZ (1) NZ504703A (ru)
OA (1) OA11900A (ru)
PE (1) PE20000125A1 (ru)
PL (1) PL341213A1 (ru)
RS (1) RS50080B (ru)
SA (1) SA99200200B1 (ru)
SK (1) SK286422B6 (ru)
TR (2) TR200001793T2 (ru)
TW (1) TW487709B (ru)
UA (1) UA66821C2 (ru)
UY (2) UY25306A1 (ru)
WO (1) WO1999031093A1 (ru)
ZA (1) ZA9811504B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
BR0009934A (pt) * 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1175418A2 (en) * 1999-04-23 2002-01-30 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
NZ525498A (en) 2000-09-26 2004-11-26 Reddys Lab Ltd Dr Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

Also Published As

Publication number Publication date
JP2002508371A (ja) 2002-03-19
HUP0102292A3 (en) 2003-12-29
KR100549141B1 (ko) 2006-02-03
AP1363A (en) 2005-01-21
BR9813598A (pt) 2000-10-10
AP2000001829A0 (en) 2000-06-30
HRP20000404A2 (en) 2000-12-31
IL160847A0 (en) 2004-08-31
GB9726563D0 (en) 1998-02-11
MA26581A1 (fr) 2004-12-20
RS50080B (sr) 2009-01-22
NO20003070D0 (no) 2000-06-15
AR017211A1 (es) 2001-08-22
MY128573A (en) 2007-02-28
UA66821C2 (ru) 2004-06-15
CZ300081B6 (cs) 2009-01-28
CZ20002206A3 (cs) 2000-12-13
BG64850B1 (bg) 2006-06-30
SK9182000A3 (en) 2000-12-11
SK286422B6 (sk) 2008-09-05
BG104606A (en) 2001-02-28
CN101318957A (zh) 2008-12-10
NO20003070L (no) 2000-06-15
EG22250A (en) 2002-11-30
EA002833B1 (ru) 2002-10-31
TW487709B (en) 2002-05-21
ID24714A (id) 2000-08-03
CN101318956A (zh) 2008-12-10
PL341213A1 (en) 2001-03-26
TR199802624A3 (tr) 1999-10-21
ZA9811504B (en) 2000-06-15
CN1285831A (zh) 2001-02-28
US20030139604A1 (en) 2003-07-24
AR016161A1 (es) 2001-06-20
US7368574B2 (en) 2008-05-06
TR200001793T2 (tr) 2000-10-23
CA2314967A1 (en) 1999-06-24
SA99200200B1 (ar) 2006-11-11
NO317255B1 (no) 2004-09-27
AU2753802A (en) 2002-05-16
AU770818B2 (en) 2004-03-04
HUP0102292A2 (hu) 2002-05-29
IL136425A (en) 2004-08-31
WO1999031093A1 (en) 1999-06-24
US20070037859A1 (en) 2007-02-15
YU36400A (sh) 2003-12-31
US20020133016A1 (en) 2002-09-19
UY25309A1 (es) 1999-07-19
PE20000125A1 (es) 2000-03-03
OA11900A (en) 2006-04-10
KR20010033140A (ko) 2001-04-25
CO4990943A1 (es) 2000-12-26
UY25306A1 (es) 2000-12-29
EP1042321A1 (en) 2000-10-11
US20050288513A1 (en) 2005-12-29
TR199802624A2 (xx) 1999-10-21
NZ504703A (en) 2002-12-20
AU2272299A (en) 1999-07-05
DZ2679A1 (fr) 2003-03-29
IL136425A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
EA200000656A1 (ru) Замещенное производное тиазолидиндиона, способ его получения и его фармацевтическое применение
EA200101119A1 (ru) Новый фармацевтический препарат
EA200101121A1 (ru) Полиморф 5-[4-[2-(n-метил-n-(2-пиридил) амино) этокси] бензил] тиазолидин-2,4-диона, соли малеиновой кислоты
EA200000654A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси]бензил]-тиазолидин-2,4-диона в качестве фармацевтического препарата
EA200000655A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
EA200101122A1 (ru) Новый фармацевтический препарат
EA200101101A1 (ru) Новый фармацевтический препарат
EA200101102A1 (ru) Новый фармацевтический препарат
EA199900879A1 (ru) Нитробензамиды, полезные в качестве антиаритмических агентов
ECSP982779A (es) Un hidrato de la sal de acido maleico, proceso para la preparacion, composicion farmaceutica y su uso en medicina
ECSP003436A (es) Nuevos compuestos
ECSP982781A (es) Hidrato de la sal de maleico de 5-[4- (-n -metil-n- (2-piridil) amino) etoxi) bensil) tiazolidina - 2,4 diona
ECSP982780A (es) Nuevo producto farmaceutico proceso para su preparacion y su uso en medicina
TH84544B (th) ไฮเดรทชนิดใหม่
ECSP003438A (es) Nuevos compuestos
ECSP003437A (es) Nuevos compuestos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU